Page 69 - วารสารการแพทย์แผนไทยและการแพทย์ ทางเลือก ปีที่ 19 ฉบับที่ 2 พฤษภาคม-สิงหาคม 2564

J Thai Trad Alt Med Vol. 19 No. 2 May-Aug 2021 299

FDA revokes emergency use authorizaition for chlo- 21. Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR,
roquine and hydroxychloroquine. [Internet]. June 2020 Cattelan AM, Viladomiu AS, Ogbuagu O, Malhotra
[cited 2021 Jun 26]; Available from: https://www.fda.gov/ P, Mullane KM, Castagna A, Chai LYA, Roestenberg
news-events/press-announcements/coronavirus-covid- M, Tsang OTY, Bernasconi E, Turnier PL, Chang SC,
19-update-fda-revokes-emergency-use-authorization- SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair
chloroquine-and. C, Wang H, Gaggar A, Brainard DM, McPhail MJ,
15. Matichon online. Dr. Surachoke Tangwiwat, FDA Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM,
warns not to use ivermectin to treat COVID-19. [Inter- GS-US-540-5774 Investigators. Effect of remdesivir vs
net]. Jun 30, 2021 [cited 2021 Jun 30]; Available from: standard care on clinical status at 11 days in patients
https://www.matichon.co.th/covid19/covid19-alert/ with moderate COVID-19: A randomized clinical trial.
news_2803628 (in Thai) JAMA 2020;324(11):1048-57.
16. Department of medical service. Guidelines for med- 22. Goldman J, Lye DCB, Hui DS, Marks KM, Bruno R,
ical practice, diagnosis, care and prevention of Montejano R, Spinner CD, Galli M, Ahn MY, Nahass
hospital infections in the case of Coronavirus Dis- RG, Chen YS, SenGupta D, Hyland RH, Osinusi AO, Cao
ease 2019 (COVID-19). [Internet]. Jul 21, 2021 [cited H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ,
2021 Jul 30]; Available from: https://covid19.dms. Muñoz J, Mullane KM, Marty FM, Tashima KT, Diaz G,
go.th/backend/Content/Content_File/Covid_Health/ Subramanian A, GS-US-540-5773 Investigators. Remde-
Attach/25640625085440AM_CPG_COVID_v.15_n%20 sivir for 5 or 10 days in patients with Severe Covid-19.
20210625.pdf (in Thai) N Engl J Med. 2020;383(19):1827-37
17. Sa-Ngiamsuntorn K, Suksatu A, Pewkliang Y, Thongsri 23. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-
P, Kanjanasirirat P, Manopwisedjaroen S, Charoensut- Restrepo AM, Preziosi MP, Sathiyamoorthy V, Karim QA,
thivarakul S, Wongtrakoongate P, Pitiporn S, Chaopre- Alejandria MM, García CH, Kieny MP, Malekzadeh R,
echa J, Kongsomros S, Jearawuttanakul K, Wannalo Murthy S, Reddy KS, Periago MR, Hanna PA, Ader F,
W, Khemawoot P, Chutipongtanate S, Borwornpinyo Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-
S, Thitithanyanont A, Hongeng S. Anti-SARS-CoV-2 Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due
Activity of Andrographis paniculata extract and its major A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N,
component andrographolide in human lung epithelial Chow TS, Como N, Eustace J, García PJ, Godbole S,
cells and cytotoxicity evaluation in major organ cell Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Has-
representatives. J Nat Prod. 2021;84(4):1261-70. sany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan
18. The Government Gazette, Volume 138, Special Section J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N,
120 Ngor, dated June 4, 2021. (in Thai) Maguire T, Manevska S, Manuel O, McGinty S, Medina
19. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, MT, Rubio MLM, Miranda-Montoya MC, Nel J, Nunes
Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine ef- EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H,
fectively inhibit the recently emerged novel coronavirus Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani
(2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71 N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen
20. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S.
BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline Repurposed antiviral drugs for COVID-19 –interim WHO
S, de Castilla DL, Finberg RW, Dierberg K, Tapson V, solidarity trial results. N Engl J Med. 2021;384(6):497-511.
Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short 24. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L,
WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz- Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S,
Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X,
Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou
Neaton JD, Burgess TH, Bonnett T, Green M, Makowski F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T,
M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW,
Members. Remdesivir for the treatment of Covid-19 - Cao B, Wang C. Remdesivir in adults with severe CO-
final report. N Engl J Med. 2020;383(19):1813-26. VID-19: a randomised, double-blind, placebo-controlled,